Table 2.
Site | Observed | Expected | SIR (95% CI) | Median time 9/11/01 to cancer diagnosis, y |
---|---|---|---|---|
All cancer sites combined | 1072 | 984.4 | 1.09 (1.02 to 1.16) | 8.6 |
Smoking-related† | 300 | 304.9 | 0.98 (0.88 to 1.10) | 8.9 |
Oral cavity and pharynx | 34 | 35.3 | 0.96 (0.67 to 1.34) | 8.3 |
Digestive system | 163 | 180.2 | 0.90 (0.77 to 1.05) | 8.6 |
Esophagus | 19 | 13.0 | 1.46 (0.88 to 2.28) | 8.2 |
Stomach | 19 | 17.8 | 1.07 (0.64 to 1.67) | 8.3 |
Colon and rectum | 68 | 84.0 | 0.81 (0.63 to 1.03) | 7.8 |
Liver and intrahepatic bile duct | 24 | 25.2 | 0.95 (0.61 to 1.42) | 9.2 |
Pancreas | 18 | 23.0 | 0.78 (0.46 to 1.24) | 9.7 |
Nose, nasal cavity, and middle ear | <5 | — | 1.14 | 8.5 |
Larynx | 10 | 12.0 | 0.83 (0.40 to 1.53) | 9.8 |
Lung and bronchus | 80 | 96.2 | 0.83 (0.66 to 1.04) | 9.2 |
Soft tissue including heart | 7 | 7.9 | 0.88 (0.35 to 1.82) | 5.2 |
Melanoma of the skin | 50 | 43.3 | 1.15 (0.86 to 1.52) | 8.6 |
Breast | 47 | 50.3 | 0.94 (0.69 to 1.24) | 8.8 |
Corpus uteri | 8 | 9.8 | 0.82 (0.35 to 1.61) | 9.6 |
Prostate | 298 | 238.7 | 1.25 (1.11 to 1.40) | 8.6 |
Testis | 10 | 14.5 | 0.69 (0.33 to 1.27) | 5.9 |
Urinary bladder | 48 | 44.2 | 1.09 (0.80 to 1.44) | 9.3 |
Kidney and renal pelvis | 54 | 46.7 | 1.16 (0.87 to 1.51) | 9.2 |
Brain and other nervous system | 21 | 15.6 | 1.34 (0.83 to 2.05) | 8.6 |
Thyroid | 73 | 33.4 | 2.19 (1.71 to 2.75) | 8.7 |
Hematological | 106 | 100.6 | 1.05 (0.86 to 1.27) | 8.4 |
Hodgkin lymphoma | 7 | 8.4 | 0.83 (0.34 to 1.72) | 6.5 |
Non-Hodgkin lymphoma | 47 | 48.8 | 0.96 (0.71 to 1.28) | 8.5 |
Myeloma | 12 | 15.0 | 0.80 (0.41 to 1.40) | 8.3 |
Leukemia | 40 | 28.4 | 1.41 (1.01 to 1.92) | 8.5 |
CLL | 12 | 11.1 | 1.08 (0.56 to 1.89) | 8.7 |
AML | 12 | 7.6 | 1.58 (0.82 to 2.76) | 8.0 |
Mesothelioma | <5 | — | 1.25 | 6.5 |
Begins 6 months past member enrollment, with enrollment beginning July 2002. AML = acute myeloid leukemia; CI = confidence interval; CLL = chronic lymphocytic leukemia.
Smoking-related cancers consist of the following cancer types: oral cavity and pharynx (excluding nasopharynx), esophagus, liver, intrahepatic bile duct, pancreas, respiratory system (excluding pleura), urinary system, and acute myeloid leukemia.